Our free daily oncology focused e-news service.
(Science Magazine) Aug 21, 2017 - This week, researchers at the Champalimaud Centre for the Unknown in Lisbon reported growing implanted human tumor cells in zebrafish larvae. Each fish became a minuscule model of a patient’s cancer—and a testbed for treatments.
read article(TUM [Munich, Germany]) Aug 22, 2017 - A new blood test developed by researchers at the Technical University of Munich (TUM) can predict drug resistance in patients with advanced prostate cancer.
read press release(Broad Institute) Aug 21, 2017 - A mutation pattern or 'signature' linked to defects in 2 genes points to other ways an important DNA repair mechanism can be shut off in breast cancer.
read article(Penn Medicine) Aug 22, 2017 - Researchers in the Perelman School of Medicine at the University of Pennsylvania found a relationship between the genetics of tumors with germline BRCA1/2 mutations and whether the tumor retains the normal copy of the BRCA1/2 gene, and risk for primary resistance to a common chemotherapy.
read press release(UNC Lineberger) Aug 21, 2017 - Jonathan Serody, MD, Benjamin Vincent, MD, and a team of UNC Lineberger investigators published findings in the Journal of Clinical Investigation that may explain why drugs designed to unleash the immune system against cancer were ineffective in treating a type of triple negative breast cancer. They determined “claudin-low” tumors were releasing a chemical signal to attract regulatory T-cells, which prevented the immune system from rejecting the cancer.
read article(Reuters) Aug 21, 2017 - Britain's Creo Medical Group said its device to remove cancerous lesions in the bowel during an endoscopy had received U.S. approval much quicker than it planned, shaking up a timetable that had been focused on a European launch.
read article(TheStreet) Aug 21, 2017 - The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.
read article(Blueprint Medicines) Aug 21, 2017 - Blueprint Medicines Corporation today announced that updated data from its ongoing Phase 1 clinical trial evaluating BLU-554 in patients with advanced hepatocellular carcinoma (HCC) will be presented in oral presentations at the European Society for Medical Oncology (ESMO) 2017 Congress on September 10, 2017 in Madrid, Spain and at the 11th International Liver Cancer Association (ILCA) Annual Conference on September 17, 2017 in Seoul, South Korea.
read corporate press release(Argos Therapeutics) Aug 21, 2017 - Argos Therapeutics Inc. today announced that an interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma (mRCC) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress to be held Sept. 8 — 12 in Madrid, Spain.
read corporate press release(Endpoints News) Aug 22, 2017 - CRISPR Therapeutics is allying with some top immuno-oncology researchers at Mass General to collaborate on some new gene editing working aimed at creating a new and better generation of T cell therapies.
read article
